Key Points
- CFO Mardi Dier sold 4,173 shares on December 2 at an average price of $578.34 for a total of $2,413,412.82, cutting her stake by 28.56% to 10,440 shares valued at roughly $6.04 million.
- Madrigal reported a significant earnings miss with quarterly EPS of ($5.08) versus analysts' ($2.01) estimate, and shows negative profitability metrics (net margin -39.04%, ROE -41.50%).
- The stock trades near $579 with a market cap of $13.17 billion and a 12‑month range of $265–$605; analysts have a consensus rating of Moderate Buy and a consensus target of $553.50.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CFO Mardi Dier sold 4,173 shares of the business's stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $578.34, for a total transaction of $2,413,412.82. Following the completion of the sale, the chief financial officer directly owned 10,440 shares of the company's stock, valued at approximately $6,037,869.60. The trade was a 28.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Madrigal Pharmaceuticals Price Performance
Shares of Madrigal Pharmaceuticals stock opened at $579.89 on Thursday. The company has a quick ratio of 3.26, a current ratio of 3.44 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $13.17 billion, a price-to-earnings ratio of -44.57 and a beta of -1.04. Madrigal Pharmaceuticals, Inc. has a twelve month low of $265.00 and a twelve month high of $605.00. The company has a 50-day simple moving average of $481.97 and a two-hundred day simple moving average of $389.67.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts' consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. Analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Institutional Investors Weigh In On Madrigal Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mather Group LLC. bought a new position in Madrigal Pharmaceuticals in the third quarter valued at about $33,000. Global Retirement Partners LLC increased its stake in shares of Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 51 shares during the period. First Horizon Corp acquired a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $34,000. AlphaQuest LLC boosted its position in Madrigal Pharmaceuticals by 412.5% during the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 66 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $39,000. Institutional investors own 98.50% of the company's stock.
Analysts Set New Price Targets
Several research firms have recently issued reports on MDGL. Bank of America raised Madrigal Pharmaceuticals from an "underperform" rating to a "neutral" rating and increased their target price for the stock from $266.00 to $445.00 in a report on Monday, November 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 8th. Canaccord Genuity Group boosted their target price on shares of Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the company a "buy" rating in a research report on Thursday, November 13th. Piper Sandler upped their price target on shares of Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the stock an "overweight" rating in a report on Wednesday, October 15th. Finally, Citigroup reissued an "outperform" rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $553.50.
View Our Latest Stock Analysis on MDGL
Madrigal Pharmaceuticals Company Profile
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
